GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$39.27 USD
-0.33 (-0.83%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $39.28 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum A VGM
Price, Consensus and EPS Surprise
GSK 39.27 -0.33(-0.83%)
Will GSK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GSK
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Why GSK (GSK) is a Top Value Stock for the Long-Term
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why GSK (GSK) is a Top Value Stock for the Long-Term
GSK Announces FDA Acceptance of New Meningococcal Jab BLA
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Other News for GSK
GSK June 21st Options Begin Trading
Dodge & Cox Global Stock Fund's 1st-Quarter Commentary: A Look Back
International Wide-Moat Stocks On Sale - The April 2024 Heat Map
GSK shingles vaccine shown 82% effective 11 years after vaccination
GSK Executives Reinvest Dividends in Shares